Marc Valentin

Director Market Access DACH EU/International Region

Frankfurt Rhine-Main Metropolitan Area

About

20 year experience in the pharmaceutical industry in various positions ranging from: - Marketing (national as well as international) - Market Access & Reimbursement - Healtheconomics & Health Care Politics Assistant Professor lecturing on HTA and Principals of Healtheconomics at a jointly conduced course run by the University of Cardiff and the University of Applied Science Fresenius (Idstein) Specialties: Immunology & Oncology

Experience

  • Director Market Access DACH & EU/International Region at Stallergenes Greer
    Apr 2020 - Present · 6 yrs 4 mos

    Leading a team to develop, manage and execute pricing and reimbursement strategies for all our products (new products like Actair/Orylmyte, extensions, revisions …) in the dedicated regions (EU5, CEE, MEA, APAC) to achieve: • reimbursement in favorable terms for patients and Stallergenes Greer at national and regional level; (Pricing & Reimbursement Dossier development & filing; price negotiations) • fair prices for products of our portfolio across a diverse set of health care systems (e.g. Germany to Romania) • rebate contracts with sick funds in DE Strong collaboration with local market access teams & HQ – functions, Regulatory Affairs, Medical as well as commercial.

  • Associate Director Market Access CEU at Illumina
    Jun 2019 - Mar 2020 · 10 mos

  • AbbVie (Wiesbaden und Umgebung, Deutschland)
    • Manager Government Affairs, Public Health & Policy
      Oct 2017 - May 2019 · 1 yr 8 mos

      Public Health • Development of managed care solutions and their implementation involving health policy actors and care providers (health insurance funds, medical associations and patient associations). Attract public funds & project management Politics • Engagement with committees and association work. Focus on eHealth and occupational health management (BGM). Member of the Vfa Expert Group on Digitization Market Access • Analysis of care paths and strategic development of care approaches via data mining cooperations with health insurance companies (therapeutic areas immunology and haemato-oncology) • Health economic cost analysis to derive dossier strategies for early benefit assessment as well as expertise in reimbursement issues (laboratory diagnostics)

    • Manager Strategic Health Initiatives
      Jan 2013 - Sep 2017 · 4 yrs 9 mos

      • Positioning AbbVie as new player towards political stakeholders by shaping the topic of "maintaining the ability to work" and bringing it to life • Sketching out and placing pharma-political demands within the framework of legislative procedures (e.g. prevention law) • Planning and implementation of tactics along themes such as "Maintaining the ability to work" through various formats such as medical training, world café formats, publications and founding of initiatives.

  • Manager Strategic Health Initiatives at Abbott Laboratories
    Apr 2012 - Dec 2012 · 9 mos

    Leading strategic health projects in immunology

  • Biotest AG (2 yrs 6 mos)
    • Senior Director Global Market Access
      Nov 2011 - Mar 2012 · 5 mos

      - Responsible for pricing and reimbursement of all pipeline and marketed products worldwide - Expertise in external reference pricing - In depth analyses on EU5 HTA readiness of our lead & pipeline candidates regarding nessacity and potential gaps - Strong knowlegde about Geman market (AMNOG, Orphans, Interaction G-BA-IQWiG)

    • Senior Director New Products
      Oct 2009 - Oct 2011 · 2 yrs 1 mo

      - Leading a team to commercialize all Phase IIb development candidates (therapeutic areas rheumatology/dermatology, oncology) - Using top down competitive methodologies as well as buttom up patient tree driven approaches to develope sound sales scenarios as well as marketing strategies & expenses feeding in to NPV calculations - Strong cross functional approach with clinical research, regulatory and controlling - KOL roadmapping & Publication planning - Key deliverables: Successful partnering deal with Abbott